Fixing genes won’t fix us
By Jim Kozubek,
Boston Globe
| 06. 01. 2017
Methadone Mile is a stretch of road along Massachusetts Avenue that begins in the South End and stretches north to the Charles River. On the other side of the river is Cambridge. For the past few years, I lived far north on this road in a $600-a-month room in a house with red paint peeling from its front clapboards. I was employed as a data scientist at the Brigham and Women’s Hospital, walking that Avenue each morning and afternoon through people in various stages of despondence, some fallen on the sidewalk, to one of my offices at the Broad Institute of MIT and Harvard.
Cambridge installed a half-million-dollar toilet near Mass. Ave in Harvard Square a year and a half ago, but that was to keep troubled people out of cafes. The big money is going toward a much different approach to longstanding social and public-health problems. Not far away, the really big, beautiful structures keep sprouting out of the ground, including Novartis’ recently completed $600 million campus, and the neighboring $1.4 billion Broad Institute with its 11 floors of...
Related Articles
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Lucy Tu, The Guardian | 11.05.2025
Beth Schafer lay in a hospital bed, bracing for the birth of her son. The first contractions rippled through her body before she felt remotely ready. She knew, with a mother’s pit-of-the-stomach intuition, that her baby was not ready either...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...